Key result
A revised nomenclature for heart failure is proposed, defining it as 'reduced' (<40%), 'mildly reduced,' and 'normal' (≥55% in men, ≥60% in women) ejection fraction.
Why the study?
The expanded indication for sacubitril/valsartan introduced a new taxonomy based on below normal ejection fraction, prompting a re-evaluation of heart failure nomenclature and evidence for neurohormonal blockade across ejection fraction ranges and sexes.
Proposes a revised heart failure classification based on ejection fraction and sex-specific thresholds to better identify patients who may benefit from neurohormonal blockade.
No takes yet. Share an insight, caveat, or question.
May refine HF phenotyping with sex-specific EF thresholds; leaves open prospective validation before practice change.
Lam et al. (2021) conducted a review in Heart failure. Sacubitril/valsartan and neurohormonal blockade was evaluated. A revised nomenclature for heart failure is proposed, defining it as 'reduced' (<40%), 'mildly reduced,' and 'normal' (≥55% in men, ≥60% in women) ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: